Clinical trials: Essential Tremor, Movement Disorders
Essential Tremor
Upper Limb Tremor Reduction in Essential Tremor Patients
This study is designed to demonstrate the safety, tolerability, and efficacy of the Encora Therapeutics Tremor Mitigation Device in subjects with upper limb tremor caused by Essential Tremor.
- Trial name
- ULTRE (NCT06343285)
- Testing
- Encora Therapeutics Tremor Reduction Device
- Where
- United States
- Volunteers
- 71 people
- Sponsor
- Encora, Inc.
Upper Extremity Tremor
123I-ALTROPANE® Reference Image Acquisition in Subjects With Diagnostically Uncertain Tremor
This study is designed to obtain an imaging training set that will be used to evaluate images in future trials. Currently, no radiopharmaceutical diagnostic imaging agent has been approved by the FDA in the U.S.
- Trial name
- AIM (NCT00596908)
- Where
- 7 sites in United States
- Volunteers
- 54 people
- Sponsor
- Alseres Pharmaceuticals, Inc
Essential Tremor
A Comparison of the Efficacy and Safety of Topiramate Versus Placebo in Treating Tremor of Unknown Cause.
The purpose of this study is to assess the safety and effectiveness of topiramate as compared to placebo in treating patients with tremor of unknown cause.
- Trial name
- NCT00236496
- Testing
- topiramate
- Volunteers
- 223 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Essential Tremor, Movement Disorders
A Proof of Concept Study of the Effectiveness of Carisbamate in the Treatment of Essential Tremor
The purpose of this study is to evaluate the effectiveness, safety and tolerability of carisbamate treatment for the signs, symptoms, and impairment associated with Essential Tremor (ET) compared to placebo treatment.
- Trial name
- NCT00524056
- Testing
- Carisbamate
- Volunteers
- 62 people
- Sponsor
- SK Life Science, Inc.
Parkinsonian Syndromes
Two Separate But Identical Studies Evaluating the Safety and Efficacy of ALTROPANE® in the Use of SPECT Imaging for Upper Extremity Tremor
This will be two separate but identical studies: ALSE-A-02a, ALSE-A02b. Each study is designed to evaluate the diagnostic accuracy and safety of a single dose of 123I-ALTROPANE® in subjects with upper extremity tremor for less…
- Trial name
- POET-2 (NCT00724906)
- Testing
- 123 I - ALTROPANE®
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Alseres Pharmaceuticals, Inc
Essential Tremor
Continued Access Protocol: ExAblate Transcranial MR Guided Focused Ultrasound for the Treatment of Essential Tremors
The objective of this prospective, multi site, single-arm study is to capture the efficacy of treatment using the ExAblate Transcranial System and to further demonstrate safety in medication-refractory tremor in patients with…
- Trial name
- NCT02289560
- Testing
- Transcranial ExAblate
- Where
- 7 sites in United States
- Volunteers
- 61 people
- Sponsor
- InSightec
Essential Tremor
directSTIM™ Deep Brain Stimulation System Post-Market Clinical Follow-up Study on Essential Tremor
This is a prospective, multi-center, single arm post-market clinical follow-up study. The present study investigates a product authorized on the European market that will be used per its intended use, and all procedures involved…
- Trial name
- NCT05795218
- Testing
- Deep Brain Stimulation
- Where
- 5 sites in Germany
- Volunteers
- 21 people
- Sponsor
- Aleva Neurotherapeutics SA
Essential Tremor
Bilateral Treatment of Medication Refractory Essential Tremor
The purpose of this study is to see if the MR-guided focused ultrasound (MRgFUS) thalamotomy procedure can be performed on both sides of the brain safely and effectively to reduce bilateral tremor.
- Trial name
- NCT04112381
- Testing
- Exablate Model 4000 Type 1.0/1.1
- Where
- 7 sites in United States
- Volunteers
- 51 people
- Sponsor
- InSightec
Parkinson's Disease, Essential Tremor
Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor
This is a 6-week exploratory clinical study, designed to test whether treatment with peroneal electrical trans-cutaneous stimulation can have a beneficial effects on symptoms associated with Parkinson's diseases and essential…
- Trial name
- NCT06036368
- Testing
- Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)
- Where
- Czechia
- Volunteers
- 23 people
- Sponsor
- Stimvia s.r.o.
Parkinsonian Syndrome, Parkinson Disease(PD)
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
This is a multicenter, open-label, non-controlled, non-randomized, phase 3 clinical study to compare the SPECT findings after a single IV administration of DaTSCAN™ ioflupane (123I) injection for patients with a clinical…
- Conditions
- Parkinsonian Syndrome, Parkinson Disease(PD), Multiple System Atrophy (MSA), Progressive Supranuclear Palsy (PSP)
- Trial name
- NCT04193527
- Testing
- DaTSCAN™ Ioflupane (123I) Injection
- Where
- 10 sites in China
- Volunteers
- 172 people, healthy volunteers welcome
- Sponsor
- GE Healthcare
Essential Tremor
A Study to Evaluate the Efficacy, Safety, and Tolerability of SAGE-324 in Participants With Essential Tremor
This is a phase 2, double-blind, placebo-controlled study to evaluate the safety and efficacy of SAGE-324 compared to placebo on upper limb (UL) tremor reduction in individuals with essential tremor (ET).
- Trial name
- NCT04305275
- Testing
- SAGE-324
- Where
- 27 sites in United States
- Volunteers
- 69 people
- Sponsor
- Sage Therapeutics
Essential Tremor
Study to Evaluate SAGE-324 in Participants With Essential Tremor
The primary purpose of this study is to evaluate the dose-response relationship of different doses of SAGE-324 on upper extremity tremor in participants with essential tremor (ET) in the monotherapy cohort.
- Trial name
- NCT05173012
- Testing
- SAGE-324
- Where
- 51 sites in United States
- Volunteers
- 146 people
- Sponsor
- Sage Therapeutics
Essential Tremor
A Clinical Trial of PRAX-944 in Participants With Essential Tremor
This is a 2-part clinical trial to evaluate the efficacy, safety, and tolerability of 40 and 120 mg oral PRAX-944 compared to placebo in the treatment of adults with essential tremor.
- Trial name
- NCT05021978
- Testing
- Part A: 20 and 40 mg PRAX-944, Part B: 120 mg PRAX-944
- Where
- 9 sites in United States, Australia and 1 more
- Volunteers
- 24 people
- Sponsor
- Praxis Precision Medicines
Essential Tremor
ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor
A feasibility Study to Evaluate Safety and Initial Effectiveness of ExAblate Transcranial MRI-guided focused ultrasound (MRgFUS) treatment of patients with medication-refractory movement disorders, namely Essential Tremor (ET).
- Trial name
- NCT02037217
- Testing
- ExAblate Transcranial MRgFUS System
- Where
- South Korea
- Volunteers
- 10 people
- Sponsor
- InSightec
Essential Tremor
T2000 in Essential Tremor - Open Label Continuation
This study will evaluate the safety and efficacy of T2000 when used to treat patients with moderate to severe essential tremor over an 18 month period.
- Trial name
- NCT00655278
- Testing
- T2000
- Where
- 3 sites in Canada
- Volunteers
- 5 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Essential Tremor
RWE Study Utilizing the Cala Trio Device in Patients With Essential Tremor
The study objective is to evaluate hand tremor relief in the treated hand following stimulation with the Cala Trio Device in adults with essential tremor, and healthcare resource utilization and total healthcare costs over a…
- Trial name
- NCT05540626
- Testing
- Cala Trio
- Where
- United States
- Volunteers
- 276 people
- Sponsor
- Cala Health, Inc.
Parkinson Disease, Essential Tremor
24-months Study to Evaluate Safety and Efficacy of Peroneal Transcutaneous NeuroModulation in Subjects With Parkinson's Disease and Essential Tremor
This study investigates the long-term safety and tolerability of home peroneal eTNM® therapy using the URIS I™ device in subjects with Parkinson's disease (PD) or Essential Tremor (ET).
- Trial name
- NCT06570421
- Testing
- Peroneal electrical transcutaneous neuromodulation (peroneal eTNM®)
- Where
- Czechia
- Volunteers
- 20 people
- Sponsor
- Stimvia s.r.o.
Parkinson Disease, Dystonia
Radiofrequency (RF) Ablation Prospective Outcomes Study for Central Nervous System - RAPID for CNS
The objective of this study is to compile real-world outcomes of Boston Scientific commercially approved radiofrequency (RF) ablation systems used in the central nervous system (CNS) for use in functional neurosurgery.
- Conditions
- Parkinson Disease, Dystonia, Essential Tremor, Movement Disorders
- Trial name
- NCT06553625
- Testing
- Radiofrequency Ablation
- Where
- 4 sites in Germany, United Kingdom
- Volunteers
- 200 people
- Sponsor
- Boston Scientific Corporation
Essential Tremor
A Pilot Efficacy and Safety Study of ST101 in Essential Tremor
This study will look at the ability of ST101 to treat symptoms in subjects with Essential Tremor. This study will also examine the safety and tolerability of the drug.
- Trial name
- NCT01332695
- Testing
- ST101
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Sonexa Therapeutics, Inc.
Essential Tremor
ExAblate Transcranial MR Guided Focused Ultrasound in the Treatment of Essential Tremor
The purpose of this study is to evaluate the safety and initial effectiveness of MRI-guided focused ultrasound thermal ablation of a designated area in the brain of patients suffering from medication-refractory Essential Tremor…
- Trial name
- NCT01304758
- Testing
- ExAblate Transcranial MRgFUS System
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- InSightec